表紙
市場調查報告書
商品編碼
989743

B肝病毒(HBV)治療藥物的全球市場-10年需求預測,COVID-19的影響:2021-2030

Global Hepatitis B Virus (HBV) Market: 10 Year Demand Forecast & Impact of COVID-19 (2021-2030)

出版日期: | 出版商: Koncept Analytics | 英文 93 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球B肝病毒(HBV)治療市場在2030年將達到356.3億美元,預計從2021年到2030年將以29.41%的複合年增長率增長。諸如製藥行業的增長,人口老齡化,醫療費用的上漲,城市化導致的最佳監測和篩查程序以及HBV引起的肝癌和肝硬化死亡人數的增加等因素正在推動市場的增長。

本報告對全球B肝病毒(HBV)治療藥物市場進行了調查和分析,並提供了有關市場規模,市場動態,競爭狀況,主要公司等的系統信息。

目錄

第1章市場概述

  • HBV:簡介
  • B型肝炎的病因
  • B型肝炎症狀
  • B肝測試與診斷
  • B型肝炎的風險
  • HBV血液檢查
  • 慢性HBV分期
  • 當前的HBV治療

第2章COVID-19的影響

  • 政府在醫療保健方面的支出增加
  • COVID-19抗病毒藥物候選者
  • 氯奎和COVID-19

第3章全球HBV市場分析

  • 全球HBV市場
  • 全球HBV市場:按抗病毒分類

第4章按地區進行的市場分析

  • 美國
    • 美國HBV市場預測:金額
    • 美國慢性HBV患者人數預測:按人數
    • 在美國對診斷為HBV的患者人數的預測:按人數
    • 對美國治療的HBV患者人數的預測:按人數
  • 歐盟
    • 歐盟HBV市場預測:金額
    • 歐盟慢性HBV患者人數預測:按人數
    • 對歐盟診斷為HBV的患者人數的預測:按人數
    • 歐盟預計治療的HBV患者人數:按人數
  • 日本
    • 日本HBV市場預測:金額

第5章市場動態

  • 生長促進因素
  • 市場趨勢
  • 挑戰

第6章競爭情況

  • 主要公司:利潤比較
  • 主要公司:研發支出比較
  • 主要公司:市值比較
  • 全世界正在開發的HBV治療方法:按公司劃分
  • 正在開發的全球衣殼抑制劑:按公司分類
  • 全球範圍內正在開發的RNAi基因抑制劑:按公司分類

第7章公司簡介

  • Johnson & Johnson
  • Merck and Co.
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Arrowhead Pharmaceuticals
  • Arbutus Pharma
目錄

The global hepatitis B virus (HBV) market is expected to reach US$35.63 billion in 2030, increasing at a CAGR of 29.41%, for the period of 2021-2030. The factors such as growth of pharmaceutical industry, increase in ageing population, upsurge in healthcare expenditure, urbanization leading to better monitoring and screening procedures and increase in liver cancer and cirrhosis deaths due to HBV would drive the growth of the market. However, the market growth would be challenged by rigid competition, management challenges, lack of diagnostic facilities and high cost of medical care and legal regulations. A few notable trends may include growth in pharmaceutical research and development, collaboration, innovation and research, high demand for biomarker based tests, HBV treatments in development and government initiatives and public awareness.

The HBV market is fragmented in nature and the degree of fragmentation would accelerate during the forecast period. To make the most of the opportunities, market players are focusing more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Key players are investing significant amount of funds on the pharmaceutical research and development in order to expand the product portfolio of hepatitis B therapeutics, which is likely to help in the considerable growth of the global hepatitis b virus (HBV) market.

The fastest regional market is the U.S., due the presence of the well established healthcare infrastructure. With the increase in the prevalence of hepatitis B, the demand for treatment of the disease is becoming prominent. Therefore, some of the government and non-government organizations are taking the initiative to bring awareness about hepatitis B, which would help in the growth of the global HBV market in coming years.

Scope of the report:

  • The report provides a comprehensive analysis of the global Hepatitis B Virus (HBV) Market.
  • The major regional markets (the U.S., European Union and Japan) have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Johnson & Johnson, Merck & Co., Bristol-Myers Squibb, Gilead Sciences, Arrowhead Pharmaceuticals and Arbutus Pharma are also presented in detail.

Key Target Audience:

  • Hepatitis B Virus Therapeutics Manufacturers
  • Pharmaceuticals and Biopharmaceutical Firms
  • End Users (Hospitals and Research Institutes)
  • Investment Banks
  • Healthcare and Medical Consultants
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1 HBV: Introduction
  • 1.2 Causes of Hepatitis B
  • 1.3 Symptoms of Hepatitis B
  • 1.4 Test and Diagnosis of Hepatitis B
  • 1.5 Risk of Hepatitis B
  • 1.6 HBV Blood Tests
  • 1.7 Chronic HBV Disease Phases
  • 1.8 Current HBV Treatments

2. Impact of COVID-19

  • 2.1 Growth in Government Spending on Healthcare
  • 2.2 COVID-19 Antiviral Drugs Candidates
  • 2.3 Chloroquine and COVID-19

3. Global HBV Market Analysis

  • 3.1 Global HBV Market
  • 3.2 Global HBV Market by Antiviral Drug Class
    • 3.2.1 Global RNA Interference Antiviral Market Forecast by Value
    • 3.2.2 Global Entry Inhibitor Antiviral Market Forecast by Value
    • 3.2.3 Global Core Inhibitor Antiviral Market Forecast by Value
    • 3.2.4 Global Antisense Antiviral Market Forecast by Value
    • 3.2.5 Global HBsAg Inhibitors Antiviral Market Forecast by Value

4. Regional Market Analysis

  • 4.1 The US
    • 4.1.1 The US HBV Market Forecast by Value
    • 4.1.2 The US Chronic HBV Patients Forecast by Volume
    • 4.1.3 The US Diagnosed HBV Patients Forecast by Volume
    • 4.1.4 The US Treated HBV Patients Forecast by Volume
  • 4.2 European Union
    • 4.2.1 European Union HBV Market Forecast by Value
    • 4.2.2 European Union Chronic HBV Patients Forecast by Volume
    • 4.2.3 European Union Diagnosed HBV Patients Forecast by Volume
    • 4.2.4 European Union Treated HBV Patients Forecast by Volume
  • 4.3 Japan
    • 4.3.1 Japan HBV Market Forecast by Value

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Expansion of Pharmaceutical Industry
    • 5.1.2 Increase in Ageing Population
    • 5.1.3 Increasing Healthcare Expenditure
    • 5.1.4 Urbanization leading to Better Monitoring and Screening Procedures
    • 5.1.5 Increase in Liver Cancer and Cirrhosis Deaths due to HBV
  • 5.2 Market Trends
    • 5.2.1 Growth in Pharmaceutical Research and Development
    • 5.2.2 Collaboration, Innovation and Research
    • 5.2.3 High Demand for Biomarker Based Tests
    • 5.2.4 HBV Treatments in Development
    • 5.2.5 Government Initiatives and Public Awareness
  • 5.3 Challenges
    • 5.3.1 Rigid Competition
    • 5.3.2 Management Challenges
    • 5.3.3 Lack of Diagnostic Facilities and High cost of Medical Care
    • 5.3.4 Legal Regulations

6. Competitive Landscape

  • 6.1 Key Players - Revenue Comparison
  • 6.2 Key Players - R&D Expenditure Comparison
  • 6.3 Key Players - Market Capitalization Comparison
  • 6.4 Global HBV Therapies in Development by Company
  • 6.5 Global Capsid Inhibitor Therapy in Development by Company
  • 6.6 Global RNAi Gene Silencer Therapy in Development by Company

7. Company Profiles

  • 7.1 Johnson & Johnson
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Merck and Co.
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Bristol-Myers Squibb
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 Gilead Sciences
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies
  • 7.5 Arrowhead Pharmaceuticals
    • 7.5.1 Business Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Business Strategies
  • 7.6 Arbutus Pharma
    • 7.6.1 Business Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Business Strategies

List of Figures

  • CHB Treatment Timeline
  • Global Government Share on Health Spending (2019-2024)
  • Global HBV Market Forecast by Value (2021-2030)
  • Global RNA Interference Antiviral Market Forecast by Value (2021-2030)
  • Global Entry Inhibitor Antiviral Market Forecast by Value (2021-2030)
  • Global Core Inhibitor Antiviral Market Forecast by Value (2021-2030)
  • Global Antisense Antiviral Market Forecast by Value (2021-2030)
  • Global HBsAg Inhibitors Antiviral Market Forecast by Value (2021-2030)
  • The US HBV Market Forecast by Value (2021-2030)
  • The US Chronic HBV Patients by Volume (2021-2030)
  • The US Diagnosed HBV Patients Forecast by Volume (2021-2030)
  • The US Treated HBV Patients Forecast by Volume (2021-2030)
  • European Union HBV Market Forecast by Value (2021-2030)
  • European Union Chronic HBV Patients Forecast by Volume (2021-2030)
  • European Union Diagnosed HBV Patients Forecast by Volume (2021-2030)
  • European Union Treated HBV Patients Forecast by Volume (2021-2030)
  • Japan HBV Market Forecast by Value (2021-2030)
  • Global Total Prescription Drugs Sales (2020-2024)
  • Global Ageing Population - Above 60+ (2021-2030)
  • Global Healthcare Expenditure (2016-2020)
  • Global Urban Population (2016-2020)
  • Global Pharmaceutical Research and Development Expenditures (2021-2030)
  • Johnson & Johnson Total Sales and Net Earnings (2015-2019)
  • Johnson & Johnson Total Sales by Segments (2019)
  • Johnson & Johnson Total Sales by Regions (2019)
  • Merck and Co. Sales and Net Income (2015-2019)
  • Merck and Co. Sales by Segments (2019)
  • Merck and Co. Sales by Regions (2019)
  • Bristol-Myers Squibb Total Revenue and Net Earnings (2015-2019)
  • Bristol-Myers Squibb Total Revenue by Operations (2019)
  • Bristol-Myers Squibb Total Revenue by Regions (2019)
  • Gilead Sciences Total Revenue and Net Income (2015-2019)
  • Gilead Sciences Total Revenue by Operations (2019)
  • Gilead Sciences Total Revenue by Regions (2019)
  • Arrowhead Pharmaceuticals Revenue and Net Income (Loss) (2016-2020)
  • Arbutus Revenue and Net Loss (2015-2019)

List of Tables

  • HBV Blood Tests and Indications
  • Chronic HBV Disease Phases
  • Key Players - Revenue Comparison (2019/2020)
  • Key Players - R&D Expenditure Comparison (2019/2020)
  • Key Players - Market Capitalization Comparison (2021)
  • Global HBV Therapies in Development by Company
  • Global Capsid Inhibitor Therapy in Development by Company
  • Global RNAi Gene Silencer Therapy in Development by Company